Ascendis Health said on Friday that its subsidiary, Remedica, had delivered revenue growth of 18% in the year to November driven by the launch of new products.
It said on Friday that Remedica “forms a material part of the company’s de-gearing strategy and continues to perform well and in line with management’s expectations”. Sardi said potential buyers may have sought to take advantage of weakness in the group’s balance sheet to extract value, but Ascendis was intent on getting a fair deal.
हमने इस समाचार को संक्षेप में प्रस्तुत किया है ताकि आप इसे तुरंत पढ़ सकें। यदि आप समाचार में रुचि रखते हैं, तो आप पूरा पाठ यहां पढ़ सकते हैं। और पढो:
इंडिया ताज़ा खबर, इंडिया मुख्य बातें
Similar News:आप इससे मिलती-जुलती खबरें भी पढ़ सकते हैं जिन्हें हमने अन्य समाचार स्रोतों से एकत्र किया है।
Market data — December 30 2019Market data including bonds, unit trusts and fuel prices
स्रोत: BDliveSA - 🏆 12. / 63 और पढो »